Cargando…

Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents

PURPOSE: Osteoporosis is a skeletal disorder characterized by reduced bone mass that results in increased risk of fractures. Pediatric osteoporosis can be caused by monogenic diseases, chronic diseases, and/or their treatment. This study was performed to investigate the effect of pamidronate infusio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Ji-Hee, Choi, Yunha, Lee, Yena, Yoo, Han-Wook, Choi, Jin-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Pediatric Endocrinology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255864/
https://www.ncbi.nlm.nih.gov/pubmed/34218632
http://dx.doi.org/10.6065/apem.2040150.075
_version_ 1783717998393032704
author Yoon, Ji-Hee
Choi, Yunha
Lee, Yena
Yoo, Han-Wook
Choi, Jin-Ho
author_facet Yoon, Ji-Hee
Choi, Yunha
Lee, Yena
Yoo, Han-Wook
Choi, Jin-Ho
author_sort Yoon, Ji-Hee
collection PubMed
description PURPOSE: Osteoporosis is a skeletal disorder characterized by reduced bone mass that results in increased risk of fractures. Pediatric osteoporosis can be caused by monogenic diseases, chronic diseases, and/or their treatment. This study was performed to investigate the effect of pamidronate infusion on osteoporosis in children and adolescents. METHODS: This study included 13 unrelated pediatric patients (10 males and 3 females) whose bone mineral density (BMD) z-score was <-2.0. Pamidronate was administered intravenously at a dosage of 1 mg/kg for 3 consecutive days every 4 months. Clinical and biochemical findings were reviewed retrospectively. The BMD values of the lumbar spine and femoral neck were assessed by dual energy x-ray absorptiometry at baseline and annually. RESULTS: The underlying diseases were immobilization (62%), inflammatory bowel disease (23%), protein-losing enteropathy (8%), and idiopathic juvenile osteoporosis (8%). The mean age at the start of treatment was 12.7±4.3 years. Duration of treatment ranged from 12–50 months. The baseline height-standard deviation score (SDS) and weight-SDS were -2.01±2.08 and -2.60±1.62, respectively. The lumbar spine BMD z-scores improved significantly after 1 year of pamidronate treatment, but the femoral neck BMD z-scores did not. However, both z-scores had significantly increased by the end of treatment. CONCLUSIONS: This study demonstrated that pamidronate treatment increased BMD in pediatric patients with osteoporosis with no significant adverse events. Further studies are required to better define the long-term efficacy and safety of pamidronate therapy in a large number of pediatric patients.
format Online
Article
Text
id pubmed-8255864
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Society of Pediatric Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-82558642021-07-15 Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents Yoon, Ji-Hee Choi, Yunha Lee, Yena Yoo, Han-Wook Choi, Jin-Ho Ann Pediatr Endocrinol Metab Original Article PURPOSE: Osteoporosis is a skeletal disorder characterized by reduced bone mass that results in increased risk of fractures. Pediatric osteoporosis can be caused by monogenic diseases, chronic diseases, and/or their treatment. This study was performed to investigate the effect of pamidronate infusion on osteoporosis in children and adolescents. METHODS: This study included 13 unrelated pediatric patients (10 males and 3 females) whose bone mineral density (BMD) z-score was <-2.0. Pamidronate was administered intravenously at a dosage of 1 mg/kg for 3 consecutive days every 4 months. Clinical and biochemical findings were reviewed retrospectively. The BMD values of the lumbar spine and femoral neck were assessed by dual energy x-ray absorptiometry at baseline and annually. RESULTS: The underlying diseases were immobilization (62%), inflammatory bowel disease (23%), protein-losing enteropathy (8%), and idiopathic juvenile osteoporosis (8%). The mean age at the start of treatment was 12.7±4.3 years. Duration of treatment ranged from 12–50 months. The baseline height-standard deviation score (SDS) and weight-SDS were -2.01±2.08 and -2.60±1.62, respectively. The lumbar spine BMD z-scores improved significantly after 1 year of pamidronate treatment, but the femoral neck BMD z-scores did not. However, both z-scores had significantly increased by the end of treatment. CONCLUSIONS: This study demonstrated that pamidronate treatment increased BMD in pediatric patients with osteoporosis with no significant adverse events. Further studies are required to better define the long-term efficacy and safety of pamidronate therapy in a large number of pediatric patients. Korean Society of Pediatric Endocrinology 2021-06 2021-06-30 /pmc/articles/PMC8255864/ /pubmed/34218632 http://dx.doi.org/10.6065/apem.2040150.075 Text en © 2021 Annals of Pediatric Endocrinology & Metabolism https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Yoon, Ji-Hee
Choi, Yunha
Lee, Yena
Yoo, Han-Wook
Choi, Jin-Ho
Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
title Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
title_full Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
title_fullStr Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
title_full_unstemmed Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
title_short Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
title_sort efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255864/
https://www.ncbi.nlm.nih.gov/pubmed/34218632
http://dx.doi.org/10.6065/apem.2040150.075
work_keys_str_mv AT yoonjihee efficacyandsafetyofintravenouspamidronateinfusionfortreatingosteoporosisinchildrenandadolescents
AT choiyunha efficacyandsafetyofintravenouspamidronateinfusionfortreatingosteoporosisinchildrenandadolescents
AT leeyena efficacyandsafetyofintravenouspamidronateinfusionfortreatingosteoporosisinchildrenandadolescents
AT yoohanwook efficacyandsafetyofintravenouspamidronateinfusionfortreatingosteoporosisinchildrenandadolescents
AT choijinho efficacyandsafetyofintravenouspamidronateinfusionfortreatingosteoporosisinchildrenandadolescents